Factor IX, recombinant (Rx)

Brand and Other Names:Rixubis, BeneFIX, more...Alprolix, Ixinity, Rebinyn, nonacog beta pegol
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

lyophilized powder for reconstitution

  • 250 IU
  • 500 IU
  • 1000 IU
  • 1500 IU
  • 2000 IU
  • 3000 IU

Hemophilia B, Bleeding Episodes

Indicated for control and prevention of bleeding episodes and perioperative management

Initial dose

  • Initial dose = body weight (kg) x desired factor IX increase (% or IU/dL) x reciprocal of observed recovery (IU/dL per IU/kg)

Incremental recovery in previously treated patients (Rixubis)

  • For incremental recovery of 0.9 IU/dL, the dose is calculated as follows:
  • Dose (IU) = body weight (kg) x desired factor IX increase (% or IU/dL) x 1.1 dL/kg

Incremental recovery in previously treated patients (BeneFIX)

  • For incremental recovery of 0.8 IU/dL, the dose is calculated as follows:
  • Dose (IU) = body weight (kg) x desired factor IX increase (% or IU/dL) x 1.3 dL/kg

Incremental recovery in previously treated patients (Ixinity)

  • For incremental recovery of 0.98 IU/dL, the dose is calculated as follows:
  • Dose (IU) = body weight (kg) x desired factor IX increase (% or IU/dL) x 1.02 dL/kg

Control and prevention of bleeding episodes (Rixubis, BeneFIX)

  • Minor: Circulating factor IX level required = 20-30 IU/dL; dosing interval 12-24 hr; treatment duration at least 1 day until healing achieved
  • Moderate: Circulating factor IX level required = 25-50 IU/dL; dosing interval 12-24 hr; treatment duration 2-7 days until bleeding stops and healing achieved
  • Major: Circulating factor IX level required = 50-100 IU/dL; dosing interval 12-24 hr; treatment duration 7-10 days until bleeding stops and healing achieved

Control and prevention of bleeding episodes (Alprolix)

  • Minor and moderate: Circulating factor IX level required = 30-60 IU/dL; dosing interval 24 hr prn
  • Major: Circulating factor IX level required = 80-100 IU/dL; consider repeating dose after 6-10 hr, then q24hr x3 days, then q48hr until healing achieved

Control and prevention of bleeding episodes (Ixinity)

  • Minor: Circulating factor IX level required = 30-60 IU/dL; dosing interval 24 hr prn; 1-3 days until healing achieved
  • Moderate: Circulating factor IX level required = 40-80 IU/dL; dosing interval 24 hr prn; 2-7 days until healing achieved
  • Major: Circulating factor IX level required = 60-100 IU/dL; dosing interval 12-24 hr prn; 2-14 days until healing achieved

Control and prevention of bleeding episodes (Rebinyn; nonacog beta pegol)

  • Minor and moderate: 40 IU/kg IV as a single dose is typically sufficient; additional doses can be give if needed
  • Major: 80 IU/kg IV; additional doses of 40 IU/kg can be given

Perioperative management (Rixubis)

  • Minor (eg, tooth extraction): Circulating factor IX level required = 30-60 IU/dL; dosing interval 24 hr; treatment duration at least 1 day until healing achieved
  • Major: Circulating factor IX level required = 80-100 IU/dL; dosing interval 8-24 hr; treatment duration 7-10 days until bleeding stops and healing achieved

Perioperative management (BeneFIX)

  • Minor: Circulating factor IX level required = 20-30 IU/dL; dosing interval 12-24 hr; treatment duration at least 1 day until healing achieved
  • Moderate: Circulating factor IX level required = 25-50 IU/dL; dosing interval 12-24 hr; treatment duration 2-7 days until bleeding stops and healing achieved
  • Major: Circulating factor IX level required = 50-100 IU/dL; dosing interval 12-24 hr; treatment duration 7-10 days until bleeding stops and healing achieved

Perioperative management (Alprolix)

  • Minor and moderate: Circulating factor IX level required = 50-80 IU/dL; a single infusion may be sufficient, may repeat as needed after 24-48 hr until bleeding stopped and healing achieved
  • Major: Circulating factor IX level required = 60-100 IU/dL (initial level); consider repeating dose after 6-10 hr, then q24hr x3 days, may then reduce dose and extend dosing interval to q48hr (or longer) until bleeding stopped and healing achieved

Perioperative management (Ixinity)

  • Minor, pre-op: Circulating factor IX level required = 50-80 IU/dL
  • Minor, post-op: Circulating factor IX level required = 30-80 IU/dL; dosing interval 24 hr; treatment duration 1-5 days depending on type of procedure
  • Major, pre-op: Circulating factor IX level required = 60-80 IU/dL
  • Major, post-op
    • Dosing interval 8-24 hr
    • Days 1-3: Circulating factor IX level required = 40-60 IU/dL
    • Days 4-6: Circulating factor IX level required = 30-50 IU/dL
    • Days 7-14: Circulating factor IX level required = 20-40 IU/dL

Perioperative management (Rebinyn)

  • Minor: 40 IU/kg IV as a single preoperative dose is typically sufficient; additional doses can be give if needed
  • Major: 80 IU/kg IV as a single preoperative dose

Hemophilia B, Routine Prophylaxis

Indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Rixubis

  • 40-60 IU/kg IV bolus 2x/week; not to exceed infusion rate of 10 mL/min
  • Dose titration may be needed depending on patient’s age, bleeding pattern, and physical activity

Alprolix

  • Long-acting recombinant Factor IX Fc fusion protein allows for less frequent dosing
  • Initial: 50 IU/kg IV once weekly OR 100 IU/kg q10days
  • Adjust dose based on individual response

Dosing Considerations

Rixubis: 1 IU/kg is expected to increase circulating level of Factor IX by 0.9 IU/dL of plasma

BeneFIX (adults): 1 IU/kg is expected to increase circulating level of Factor IX by 0.8 IU/dL (range 0.4-1.2 IU/dL)

Alprolix: 1 IU/kg is expected to increase circulating level of Factor IX by 1% (IU/dL)

Rebinyn: Conjugated to a 40-kDa polyethylene glycol molecule, which slows down its removal from the blood circulation; each vial is labeled with the actual Factor IX potency in IU

Dosage Forms & Strengths

lyophilized powder for reconstitution

  • 250 IU
  • 500 IU
  • 1000 IU
  • 1500 IU
  • 2000 IU
  • 3000 IU

Hemophilia B, Bleeding Control

BeneFIX: Approved for children <15 yr; indicated for control and prevention of bleeding episodes and perioperative management

Ixinity: Approved for children ≥12 yr; indicated for control and prevention of bleeding episodes and perioperative management

Alprolix, Rixubix: Approved for children; indicated for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent/reduce frequency of bleeding episodes

Initial dose

  • Initial dose = body weight (kg) x desired factor IX increase (% or IU/dL) x reciprocal of observed recovery (IU/dL per IU/kg)

Incremental recovery in previously treated patients (BeneFIX)

  • For incremental recovery of 0.7 IU/dL, the dose is calculated as follows:
  • Dose (IU) = body weight (kg) x desired factor IX increase (% or IU/dL) x1.4 dL/kg

Incremental recovery in previously treated patients (Ixinity)

  • For incremental recovery of 0.98 IU/dL, the dose is calculated as follows:
  • Dose (IU) = body weight (kg) x desired factor IX increase (% or IU/dL) x 1.02 dL/kg

Control and prevention of bleeding episodes (BeneFIX)

  • Minor: Circulating factor IX level required = 20-30 IU/dL; dosing interval 12-24 hr; treatment duration at least 1 day until healing achieved
  • Moderate: Circulating factor IX level required = 25-50 IU/dL; dosing interval 12-24 hr; treatment duration 2-7 days until bleeding stops and healing achieved
  • Major: Circulating factor IX level required = 50-100 IU/dL; dosing interval 12-24 hr; treatment duration 7-10 days until bleeding stops and healing achieved

Control and prevention of bleeding episodes (Alprolix)

  • Minor and moderate: Circulating factor IX level required = 30-60 IU/dL; dosing interval 24 hr prn
  • Major: Circulating factor IX level required = 80-100 IU/dL; consider repeating dose after 6-10 hr, then q24hr x3 days, then q48hr until healing achieved

Control and prevention of bleeding episodes (Ribuxis)

  • Minor: Circulating factor IX level required = 20-30 IU/dL; dosing interval 12-24 hr prn; at least 1 day until healing achieved
  • Moderate: Circulating factor IX level required = 25-50 IU/dL; dosing interval 12-24 hr prn; at least 2-7 days until healing achieved
  • Major: Circulating factor IX level required = 50-100 IU/dL; dosing interval 12-24 hr prn; at least 7-10 days until healing achieved

Control and prevention of bleeding episodes (Ixinity)

  • Minor: Circulating factor IX level required = 30-60 IU/dL; dosing interval 24 hr prn; 1-3 days until healing achieved
  • Moderate: Circulating factor IX level required = 40-80 IU/dL; dosing interval 24 hr prn; 2-7 days until healing achieved
  • Major: Circulating factor IX level required = 60-100 IU/dL; dosing interval 12-24 hr prn; 2-14 days until healing achieved

Control and prevention of bleeding episodes (Rebinyn; nonacog beta pegol)

  • Minor and moderate: 40 IU/kg IV as a single dose is typically sufficient; additional doses can be give if needed
  • Major: 80 IU/kg IV; additional doses of 40 IU/kg can be given

Perioperative management (BeneFIX)

  • Minor: Circulating factor IX level required = 20-30 IU/dL; dosing interval 12-24 hr; treatment duration at least 1 day until healing achieved
  • Moderate: Circulating factor IX level required = 25-50 IU/dL; dosing interval 12-24 hr; treatment duration 2-7 days until bleeding stops and healing achieved
  • Major: Circulating factor IX level required = 50-100 IU/dL; dosing interval 12-24 hr; treatment duration 7-10 days until bleeding stops and healing achieved

Perioperative management (Alprolix)

  • Minor and moderate: Circulating factor IX level required = 50-80 IU/dL; a single infusion may be sufficient, may repeat as needed after 24-48 hr until bleeding stopped and healing achieved
  • Major: Circulating factor IX level required = 60-100 IU/dL (initial level); consider repeating dose after 6-10 hr, then q24hr x3 days, may then reduce dose and extend dosing interval to q48hr (or longer) until bleeding stopped and healing achieved

Perioperative management (Rixubis)

  • Minor: Circulating factor IX level required = 30-60 IU/dL; dosing interval 24 hr; at least 1 day until healing achieved
  • Major: Circulating factor IX level required = 80-100 IU/dL; dosing interval 8-24 hr; at least 7-10 days until healing achieved

Perioperative management (Ixinity)

  • Minor, pre-op: Circulating factor IX level required = 50-80 IU/dL
  • Minor, post-op: Circulating factor IX level required = 30-80 IU/dL; dosing interval 24 hr; treatment duration 1-5 days depending on type of procedure
  • Major, pre-op: Circulating factor IX level required = 60-80 IU/dL
  • Major, post-op
    • Dosing interval 8-24 hr
    • Days 1-3: Circulating factor IX level required = 40-60 IU/dL
    • Days 4-6: Circulating factor IX level required = 30-50 IU/dL
    • Days 7-14: Circulating factor IX level required = 20-40 IU/dL

Perioperative management (Rebinyn)

  • Minor: 40 IU/kg IV as a single preoperative dose is typically sufficient; additional doses can be give if needed
  • Major: 80 IU/kg IV as a single preoperative dose

Hemophilia B, Routine Prophylaxis

Indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes

Alprolix

  • Long-acting recombinant Factor IX Fc fusion protein allows for less frequent dosing
  • Initial: 50 IU/kg IV once weekly OR 100 IU/kg q10days
  • Adjust dose based on individual response

Rixubis

  • <12 years: 60-80 IU/kg IV 2x/week
  • ≥12 years: 40-60 IU/kg IV 2x/week
  • Maximum infusion rate is 10 mL/min
  • Adjust the dose based on the individual patient’s age, bleeding pattern, and physical activity

Dosing Considerations

BeneFIX (children <15 years): 1 IU/kg is expected to increase circulating level of Factor IX by 0.7 IU/dL (range 0.2-2.1 IU/dL)

Alprolix: 1 IU/kg is expected to increase circulating level of Factor IX by 1% (IU/dL)

Alprolix (<12 years): May have higher Factor IX bodyweight-adjusted clearance, shorter half-life, and lower recovery; therefore, higher dose/kg or more frequent dosing may be needed

Rixubis (<12 years): 1 IU/kg is expected to increase circulating level of Factor IX by 0.7 IU/dL

Rixubis (≥12 years): 1 IU/kg is expected to increase circulating level of Factor IX by 0.9 IU/dL

Rebinyn: Conjugated to a 40-kDa polyethylene glycol molecule, which slows down its removal from the blood circulation; each vial is labeled with the actual Factor IX potency in IU

Next:

Adverse Effects

>10% (BeneFIX)

Headache (10.8%)

1-10% (BeneFIX)

Dizziness (7.7%)

Injection site reaction (7.7%)

Injection site pain (6.2%)

Nausea (6.2%)

Rash (6.2%)

Taste perversion (4.6%)

Hives (3.1%)

Flushing (3.1%)

Fever (3.1%)

Factor IX inhibition (1.5%)

Blurred vision (1.5%)

Vomiting (1.5%)

Cellulitis at IV site (1.5%)

Phlebitis at IV site (1.5%)

Shaking (1.5%)

Drowsiness (1.5%)

Renal infarct (1.5%)

Dry cough (1.5%)

Hypoxia (1.5%)

Chest tightness (1.5%)

1-10% (Rixubis)

Factor IX or furin antibodies (7.7%)

Dysgeusia (1.1%)

Pain in extremity (1.1%)

Positive furin antibody test (1.1%)

1-10% (Alprolix)

Headache (1.7%)

Oral paresthesia (1.7%)

<1% (Alprolix)

Dizziness

Dysgeusia

Breath odor

Fatigue

Infusion site pain

Palpitations

Obstructive uropathy

Hypotension

Previous
Next:

Warnings

Contraindications

Hypersensitivity to product or its excipients including hamster protein

Disseminated intravascular coagulation (DIC)

Signs of fibrinolysis

Cautions

Hypersensitivity reactions including anaphylaxis reported, particularly with initial exposure in previously untreated patients Factor IX inhibitors may develop

Nephrotic syndrome reported

Thromboembolic complications may occur (eg, PE, venous or arterial thrombosis); monitor for thrombotic and consumptive coagulopathy, especially in patients with liver disease, signs of fibrinolysis, peri- and post-operatively, or at risk for thrombotic events or DIC

Monitor Factor IX activity plasma levels by the one-stage clotting assay to confirm factor IX levels achieved and maintained

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: C

Lactation: Unknown if distributed in human breast milk

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Temporarily replaces missing clotting factor IX which corrects and/or prevents bleeding

Absorption

Rixubis

  • Peak plasma concentration: 66.2-72.7 IU/dL
  • AUC: 1207-1305 IU•hr/dL

BeneFIX

  • Peak plasma concentration: 54.5 IU/dL
  • AUC: 548-940 IU•hr/dL

Alprolix

  • Peak plasma concentration: 46 IU/dL
  • 1619 IU•hr/dL

Rebinyn

  • Peak plasma concentration: 65.5-97.9 IU/d
  • AUC: 9072-9280 IU·hr/dL

Distribution

Rixubis

  • Vd: 201.9-178.6 mL/kg

Alprolix

  • Vd: 327 mL/kg

Rebinyn

  • Vd: 60.5-64.8 mL/kg

Elimination

Rixubis

  • Half-life: 25.4-26.7 hr
  • Clearance: 6-6.4 mL/kg/hr

BeneFIX

  • Half-life: 18.1-22.4 hr (adults); 19.8 hr (children 2-12 years); 21.1 hr (children 12-15 years)
  • Clearance: ~8.5 mL/kg/hr

Alprolix

  • Half-life: 86.52 hr
  • Clearance: 3.3 mL/kg/hr

Rebinyn

  • Half-life: 103.1-114.9 hr
  • Clearance: 0.4 mL/hr/kg
Previous
Next:

Administration

IV Preparation

BeneFIX, Alprolix, Rebinyn: Use the adapter and supplied diluent syringe to reconstitute each vial (see package instructions)

Rixubis: Use the Baxject II device and sterile water for injection provided in each kit to reconstitute each vial (see package instructions)

IV Administration

Safety and efficacy of administration by continuous infusion has not been established

BeneFIX: Administer IV over several minutes

Rixubis, Alprolix: Administer by IV bolus at rate not to exceed 10 mL/min

Rebinyn: Administer IV over 1-4 minutes

Storage

Unopened vials

  • Refrigerated: Store between 2-8°C (35-46°F) in original carton for up to 18 months; do not freeze
  • Room temperature: May store at room temperature, not to exceed 30°C (86°F) for up to 6 months within the 18 month time period (mark carton on date removed from refrigerator)
  • After storage at room temperature, do not return the product to the refrigerator

Reconstituted vials

  • Use within 3 hr following reconstitution
  • Do not refrigerate after reconstitution
  • Discard partially used vials
Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.